Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713154 | 0.97 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53LMNAUTS2RCNR1 | |
| SCHEMBL12713278 | 0.88 | GPR119 (0.47) | SMN1; SMN2TP53LMNACNR1POLB | |
| SCHEMBL12713153 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53CNR1STSPOLB | |
| SCHEMBL12713087 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2TP53LMNAUTS2RCNR1 | |
| SCHEMBL12713138 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2TP53CNR1STSPOLB | |
| SCHEMBL12713105 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2TP53LMNAUTS2RCNR1 | |
| SCHEMBL12713199 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53UTS2RCNR1STS | |
| SCHEMBL12713072 | 0.82 | UTS2R (0.46) | SMN1; SMN2TP53LMNAUTS2RCNR1 | |
| SCHEMBL14431138 | 0.82 | HRH2 (0.48) | LMNA | |
| SCHEMBL13002965 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2TP53LMNAUTS2RCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2020405-A1 | Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007115798-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| EP-1842846-A1 | Phenylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007096186-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| EP-1826201-A1 | Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | SMN1; SMN2 1344/4885TP53 3292/4885LMNA 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.